Press Releases Year None202020192018201720162015 Dec 16, 2020 Ovid Therapeutics Announces Addition to the Nasdaq Biotechnology Index Dec 01, 2020 Ovid Therapeutics Announces Phase 3 NEPTUNE Clinical Trial of OV101 for the Treatment of Angelman Syndrome Did Not Meet Primary Endpoint Nov 23, 2020 Ovid Therapeutics to Present at the American Epilepsy Society (AES) 2020 Virtual Congress Nov 12, 2020 Ovid Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update Oct 14, 2020 Ovid Therapeutics to Host Educational Webinar on Angelman Syndrome and OV101 Development Program Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Next page next › Last page last »
